Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.8K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.8K
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

333
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
333
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

291
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
291
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

335
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
335
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

256
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
256
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

1.9K
Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
1.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Antibiotic Outcomes of Enterococcal Urinary Tract Infections: A Retrospective Analysis from Saudi Arabia and Oman.

Pathogens (Basel, Switzerland)·2026
Same author

Alternatives to traditional pharmacy internships: a scoping review protocol.

JBI evidence synthesis·2025
Same author

Antibiotic Use Among Hospitalized Patients with COVID-19 Infection (SARS-CoV-2 Omicron Variant) in Oman: A Single-center Retrospective Study.

Oman medical journal·2025
Same author

COVID-19 vaccine hesitancy among healthcare workers in Arab Countries: A systematic review and meta-analysis.

PloS one·2024
Same author

Exploring the reasons behind low COVID-19 vaccination coverage in ethnic minorities-A qualitative study among Arabic-speaking public in Denmark.

Health policy (Amsterdam, Netherlands)·2023
Same author

Views and perceptions of the public toward COVID-19 vaccine in Saudi Arabia.

Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society·2023

Related Experiment Video

Updated: Mar 24, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.2K

Statins and its hepatic effects: Newer data, implications, and changing recommendations.

Jimmy Jose1

  • 1Department of Pharmacy Practice, School of Pharmacy, University of Nizwa, Birkat Al Mouz, Nizwa, Sultanate of Oman.

Journal of Pharmacy & Bioallied Sciences
|March 10, 2016
PubMed
Summary

Statins have a very low risk of serious liver injury, despite common fears. These cholesterol-lowering drugs can be safely used in most patients with existing liver conditions.

Keywords:
Hepatic effectsimplicationsrecommendationsstatins

More Related Videos

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

14.2K
Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
08:58

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Published on: March 11, 2017

17.2K

Related Experiment Videos

Last Updated: Mar 24, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.2K
LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

14.2K
Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
08:58

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Published on: March 11, 2017

17.2K

Area of Science:

  • Pharmacology
  • Hepatology
  • Cardiovascular Medicine

Background:

  • Hepatic adverse effects are a common concern with statin therapy.
  • Fear of liver issues leads to statin underutilization and discontinuation.
  • Current data on statin-induced liver injury and management strategies are evolving.

Purpose of the Study:

  • To review the actual risk of serious hepatic adverse effects from statins.
  • To provide guidance on monitoring and safety in patients with pre-existing liver conditions.
  • To address the impact of fear on statin prescribing and patient adherence.

Main Methods:

  • Literature review of studies on statin-associated liver injury.
  • Analysis of current recommendations for monitoring liver function.
  • Evaluation of statin safety in specific liver disease populations.

Main Results:

  • Statins are associated with a very low risk of true, serious liver injury.
  • Routine liver function monitoring may not be effective in preventing or detecting serious injury.
  • Statin therapy is generally safe in patients with nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and compensated cirrhosis.

Conclusions:

  • Overstated fears of statin hepatotoxicity can deny patients significant cardiovascular benefits.
  • Physician judgment is crucial for balancing risks and benefits in individual patients.
  • Statin use should not be avoided in indicated patients with pre-existing liver conditions, with careful consideration.